These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 22387885

  • 1. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
    Zhou L, Chen H, Wen Q, Zhang Y.
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):695-701. PubMed ID: 22387885
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.
    Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H.
    Clin Immunol; 2004 Oct; 113(1):47-55. PubMed ID: 15380529
    [Abstract] [Full Text] [Related]

  • 3. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, Abrignani S, Reali E.
    Inflamm Bowel Dis; 2013 Oct; 19(4):729-39. PubMed ID: 23448791
    [Abstract] [Full Text] [Related]

  • 4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 5. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 6. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase.
    Ferdinande L, Demetter P, Perez-Novo C, Waeytens A, Taildeman J, Rottiers I, Rottiers P, De Vos M, Cuvelier CA.
    Int J Immunopathol Pharmacol; 2008 Feb 15; 21(2):289-95. PubMed ID: 18547472
    [Abstract] [Full Text] [Related]

  • 7. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A, Støy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Møller HJ, Grønbaek H.
    Scand J Immunol; 2014 Dec 15; 80(6):417-23. PubMed ID: 25346048
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Indoleamine 2,3-dioxygenase and regulatory t cells in intestinal mucosa in children with inflammatory bowel disease.
    Sznurkowska K, Żawrocki A, Sznurkowski J, Iżycka-Świeszewska E, Landowski P, Szlagatys-Sidorkiewicz A, Plata-Nazar K, Kamińska B.
    J Biol Regul Homeost Agents; 2017 Dec 15; 31(1):125-131. PubMed ID: 28337881
    [Abstract] [Full Text] [Related]

  • 10. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease.
    Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CB, Verspaget HW.
    J Pathol; 2003 Sep 15; 201(1):7-16. PubMed ID: 12950012
    [Abstract] [Full Text] [Related]

  • 11. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I, Hasan F, Khan I.
    Scand J Gastroenterol; 2009 Sep 15; 44(1):56-64. PubMed ID: 18785066
    [Abstract] [Full Text] [Related]

  • 12. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.
    Am J Gastroenterol; 2001 Oct 15; 96(10):2946-56. PubMed ID: 11693331
    [Abstract] [Full Text] [Related]

  • 13. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 14. Expression of 4C8 antigen, a novel transendothelial migration-associated molecule on activated T lymphocytes, in inflammatory bowel disease.
    Oshitani N, Hato F, Kitagawa S, Masuyama J, Higuchi K, Matsumoto T, Arakawa T.
    J Pathol; 2002 Aug 01; 197(5):589-94. PubMed ID: 12210077
    [Abstract] [Full Text] [Related]

  • 15. Profile of soluble cytokine receptors in Crohn's disease.
    Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Devière J, Franchimont D.
    Gut; 2005 Apr 01; 54(4):488-95. PubMed ID: 15753533
    [Abstract] [Full Text] [Related]

  • 16. Indoleamine 2,3-dioxygenase: expressing cells in inflammatory bowel disease-a cross-sectional study.
    Furuzawa-Carballeda J, Fonseca-Camarillo G, Lima G, Yamamoto-Furusho JK.
    Clin Dev Immunol; 2013 Apr 01; 2013():278035. PubMed ID: 24282429
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Rutgeerts P, Vermeire S, Van Assche G.
    Gut; 2007 Apr 01; 56(4):453-5. PubMed ID: 17369375
    [Abstract] [Full Text] [Related]

  • 19. [Inflammatory diseases of the intestines].
    Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P.
    Rev Med Suisse; 2006 Jan 18; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of chronic inflammatory bowel diseases].
    Lémann M.
    Bull Acad Natl Med; 2007 Jun 18; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.